Inhibitory member of the ASPP family (iASPP) acts as inhibitor for the p53, and its expression is upregulated in human breast carcinomas expressing wild-type p53. To examine the role of iASPP in acute leukemia patients, we analysed iASPP mRNA expression in AL by semi quantitative reverse transcriptase polymerase chain reaction (RT-PCR). The results showed that the median level of iASPP in ALL and AML patients are significantly higher than those in cells from normal donors (p=0.04). The expression of iASPP in ALL and AML patients were not associated with age, gender, hemoglobin, platelets, blasts count in bone marrow, treatment outcome but were associated with blasts count in peripheral blood and total leucocytic count in AML patients. The results of the present study my suggest that iASPP may play a role in leukemogenesis and or disease progression of AL.